In 2016 the European Haemophilia Consortium (EHC) received funding from the below income sources. The accounts of the EHC are audited by an external auditor and approved by its members during its Annual General Assembly.

 

 

 


EHC Funding 2016 - Industry versus non-industry funding

Source of incomeAmount in €% of the total income
Non-industry432,12629%
Industry1,082,25071%
Highest industry contribution435,00029%

EHC non-industry funding - 2016

Funding source Amount in €% of the total income
EHC membership and other fees13,3001%
EHC Conference income85,5286%
European Commission co-funding (CHAFEA)36,5982%
Volunteer (non-remunerated) contributions296,70020%
Subtotal432,12629%

EHC industry-related funding - 2016

Funding sourceAmount in €% of total income
Abbvie
20,0001
Alnylam8,7501
Baxalta/Shire435,00029
Bayer40,0003
Biotest17,5001
BioMarin15,0001
CSL Behring40,0003
Grifols35,0002
Kedrion7,5000
Novo Nordisk100,0007
Pfizer90,0006
PPTA5,0000
Roche90,0006
Sobi178,50012
Subtotal1,082,25071